The BDNF Val66Met polymorphism is associated with escitalopram response in depressed patients

Psychopharmacology

Volumn 232, Issue 3, 2015, Pages 575-581

  El Hage, Wissam ^a,b   Vourc'H, Patrick ^a,b   Gaillard, Philippe ^a,b   Léger, Julie ^a   Belzung, Catherine ^b   Ibarguen Vargas, Yadira ^c   Andres, Christian R ^a,b   Camus, Vincent ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Depression BDNF; Escitalopram; SSRI; Treatment resistant depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; METHIONINE; SEROTONIN UPTAKE INHIBITOR; VALINE;

ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; METHIONINE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; VALINE; YOUNG ADULT;

EID: 84922149634     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3694-z     Document Type: Article

References (43)

1. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM (2008) Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 63(7):642-649. doi: 10.1016/j.biopsych.2007.09.019
2. Akinfiresoye L, Tizabi Y (2013) Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacol (Berl) 230(2):291-298. doi: 10.1007/s00213-013-3153-2
3. Alexopoulos GS, Glatt CE, Hoptman MJ, Kanellopoulos D, Murphy CF, Kelly RE Jr, Morimoto SS, Lim KO, Gunning FM (2010) BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord 125(1-3):262-268. doi: 10.1016/j.jad.2010.02.115
4. Anastasia A, Deinhardt K, Chao MV, Will NE, Irmady K, Lee FS, Hempstead BL, Bracken C (2013) Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat Commun 4:2490. doi: 10.1038/ncomms3490
5. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM (2013) Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 38:377-385. doi: 10.1038/npp.2012.191
6. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004) Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24(18):4401-4411. doi: 10.1523/JNEUROSCI.0348-04.2004
7. Chi MH, Chang HH, Lee SY, Lee IH, Gean PW, Yang YK, Lu RB, Chen PS (2010) Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord 126:430-435. doi: 10.1016/j.jad.2010.07.006
8. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS (2006) Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118:176-182. doi: 10.1016/j.brainres.2006.08.012
9. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-758. doi: 10.1016/S0140-6736(09)60046-5
10. Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, Deckert J, Arolt V, McMahon FJ, Baune BT (2010) Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 13(1):93-101. doi: 10.1017/S1461145709000030
11. D'Sa C, Duman RS (2002) Antidepressants and neuroplasticity. Bipolar Disord 4:183-194. doi: 10.1034/j.1399-5618.2002.01203.x
12. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257-269. doi: 10.1016/S0092-8674(03)00035-7
13. El-Hage W, Powell JF, Surguladze SA (2009) Vulnerability to depression: what is the role of stress genes in gene x environment interaction? Psychol Med 39:1407-1411. doi: 10.1017/S0033291709005236
14. El-Hage W, Leman S, Camus V, Belzung C (2013) Mechanisms of antidepressant resistance. Front Pharmacol 4:146. doi: 10.3389/fphar.2013.00146
15. Ibarguen-Vargas Y, Surget A, Vourc'h P, Leman S, Andres CR, Gardier AM, Belzung C (2009) Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 202:245-251. doi: 10.1016/j.bbr.2009.03.040
16. Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473-500. doi: 10.1038/mp.2008.116
17. Keith SJ, Matthews SM (1993) The value of psychiatric treatment: its efficacy in severe mental disorders. Psychopharmacol Bull 29:427-430
18. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Mendlewicz J, Noro M, Montgomery S, Oswald P, Snyder L, Zohar J, Souery D (2011) Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 26(1):1-10. doi: 10.1097/YIC.0b013e32833d18f8
19. Lépine JP, Briley M (2011) The increasing burden of depression. Neuropsychiatr Dis Treat 7(S1):3-7. doi: 10.2147/NDT.S19617
20. Lin HL, Hsu YT, Liu CY, Chen CH, Hsiao MC, Liu YL, Shen WW, Hsiao CF, Liu SI, Chang LH, Tang HS, Lai HL, Lin PS, Lin KM, Tsou HH (2013) Comparison of escitalopram and paroxetine in the treatment of major depressive disorder. Int Clin Psychopharmacol 28(6):339-345. doi: 10.1097/YIC.0b013e32836458e2
21. Martocchia A, Curto M, Scaccianoce S, Comite F, Xenos D, Nasca C, Falaschi GM, Ferracuti S, Girardi P, Nicoletti F, Falaschi P (2014) Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report. Aging Clin Exp Res. doi: 10.1007/s40520-014-0194-2
22. Mikoteit T, Beck J, Eckert A, Hemmeter U, Brand S, Bischof R, Holsboer-Trachsler E, Delini-Stula A (2014) High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression. Psychopharmacol (Berl). doi: 10.1007/s00213-014-3475-8
23. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, Meuth S, Nagy A, Greene RW, Nestler EJ (2004) Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A 101(29):10827-10832. doi: 10.1073/pnas.0402141101
24. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. doi: 10.1192/bjp.134.4.382
25. Munno D, Sterpone S, Fania S, Cappellin F, Mengozzi G, Saroldi M, Bechon E, Zullo G (2013) Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine. Panminerva Med 55(4):377-384
26. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349:1436-1442. doi: 10.1016/S0140-6736(96)07495-8
27. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547
28. Nikolac Perkovic M, Nedic Erjavec G, Zivkovic M, Sagud M, Uzun S, Mihaljevic-Peles A, Kozumplik O, Muck-Seler D, Pivac N (2014) Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacol (Berl). doi: 10.1007/s00213-014-3515-4
29. Philip SP, Carpenter LL, Tyrka AR, Price LH (2010) Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother 11:709-722. doi: 10.1517/14656561003614781
30. Ramos-Quiroga JA, Corominas-Roso M, Palomar G, Gomez-Barros N, Ribases M, Sanchez-Mora C, Bosch R, Nogueira M, Corrales M, Valero S, Casas M (2014) Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacol (Berl) 231(7):1389-1395. doi: 10.1007/s00213-013-3343-y
31. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, Ernfors P, Castrén E (2003) Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23(1):349-357
32. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(S20):22-33
33. Steve M, Bruce A, Simon H, Simon O, Ian R, Frank S, Brian W, Iain C (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326(7397):1014. doi: 10.1136/bmj.326.7397.1014
34. Tabagh R, Andres C, Vedrine S, Cherpi-Antar C, Thepault RA, Mignon L, Dufour-Rainfray D, Moraine C, Vourc'h P (2010) Study of the serotonin transporter (SLC6A4) and BDNF genes in French patients with non syndromic mental deficiency. BMC Med Genet 11:30. doi: 10.1186/1471-2350-11-30
35. Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, Henigsberg N, Mendlewicz J, Aitchison KJ, Farmer A, McGuffin P (2011) Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry 72(11):1478-1484. doi: 10.4088/JCP.10 m06419
36. Warner-Schmidt JL, Duman RS (2006) Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16(3):239-249. doi: 10.1002/hipo.20156
37. Watanabe K, Hashimoto E, Ukai W, Ishii T, Yoshinaga T, Ono T, Tateno M, Watanabe I, Shirasaka T, Saito S, Saito T (2010) Effect of antidepressants on brain-derived neurotrophic factor (BDNF) release from platelets in the rats. Prog Neuropsychopharmacol Biol Psychiatry 34(8):1450-1454. doi: 10.1016/j.pnpbp.2010.07.036
38. Xu G, Lin K, Rao D, Dang Y, Ouyang H, Mai G, Zhang M (2012) Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. Psychiatr Genet 22(4):214-215. doi: 10.1097/YPG.0b013e32834c0c87
39. Yoshimura R, Kishi T, Suzuki A, Umene-Nakano W, Ikenouchi-Sugita A, Hori H, Otani K, Iwata N, Nakamura J (2011) The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 35:1022-1025. doi: 10.1016/j.pnpbp.2011.02.009
40. Zarate CA, Mathews DC, Furey ML (2013) Human biomarkers of rapid antidepressant effects. Biol Psychiatry 73:1142-1155. doi: 10.1016/j.biopsych.2012.11.031
41. Zhang XY, Liang J, da Chen C, Xiu MH, Yang FD, Kosten TA, Kosten TR (2012) Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacol (Berl) 222(2):277-284. doi: 10.1007/s00213-012-2643-y
42. Zou YF, Wang Y, Liu P, Feng XL, Wang BY, Zang TH, Yu X, Wei J, Liu ZC, Liu Y, Tao M, Li HC, Li KQ, Hu J, Li M, Zhang KR, Ye DQ, Xu XP (2010a) Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Hum Psychopharmacol 25(2):145-152. doi: 10.1002/hup.1099
43. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF (2010b) Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 20:535-544. doi: 10.1016/j.euroneuro.2009.12.005